Chlorophyllin shows promise for radiation-induced bladder bleeding in phase II trial

Cancer survivors who undergo pelvic radiation face a particular kind of aftermath: bleeding from the bladder that won't stop. It happens to somewhere between one in twenty and one in six patients treated this way, a complication called chronic hemorrhagic cystitis that can persist for years, draining quality of life in ways both obvious and grinding. For decades, there has been no reliable fix. Now a phase II trial suggests that a simple oral compound—a chlorophyll derivative called sodium-copper-chlorophyllin—might offer real relief.

The CLARITY trial enrolled twenty-four patients, most of them survivors of cervical cancer, who had been bleeding from their bladders for at least three months after completing pelvic radiotherapy. Fifteen had cervical cancer, five had rectal cancer, and four had prostate cancer. When they entered the study, their bleeding was severe: most were in grade 3 territory on the standard severity scale, meaning significant hematuria; one patient was at grade 4, the worst category. Six others were at grade 2. These were people who had already endured cancer treatment and were now living with a painful, disruptive side effect that conventional medicine had largely abandoned them to manage.

For twelve weeks, each participant took 750 milligrams of chlorophyllin by mouth each day. The researchers were measuring whether the bleeding would improve—either disappear entirely or at least get better. What they found was striking: seventy-one percent of the patients saw meaningful improvement. Nine achieved complete remission of their bleeding. Eight more saw it diminish substantially. The median time before improvement showed up was about two months. Once it did, the benefit held for a median of ten months.

What made this result particularly notable was how well the drug was tolerated. Nobody quit the trial because of side effects. No one experienced severe adverse events. The most common complaint was a greenish discoloration of stool, which occurred in nearly four out of five patients—an aesthetic nuisance but nothing more. Nausea appeared in one out of six. These are the kinds of trade-offs patients can actually live with, especially when weighed against the alternative of ongoing bleeding and the urinary dysfunction that comes with it.

Beyond the raw response numbers, patients reported real gains in their daily lives. Their urinary function improved. The bother and disruption they felt diminished. Their overall health and quality of life scores on standardized measures climbed significantly. For cancer survivors already years past their initial treatment, this kind of functional recovery matters enormously. It means fewer bathroom emergencies, less pain, less anxiety about bleeding episodes.

The mechanism remains partly mysterious, though laboratory analysis of blood proteins suggested the drug was working through multiple pathways—dampening inflammation, modulating the body's clotting and complement systems, reducing oxidative stress, and apparently triggering repair processes in the bladder tissue itself. This is not a single-bullet explanation but rather a compound effect across several biological systems, which may explain why it works when simpler interventions have failed.

The trial was small and conducted at a single center, which is typical for phase II work. The researchers enrolled everyone who met criteria rather than randomly assigning some to placebo, which means the results are encouraging but not yet definitive proof. What happens next is the logical step: larger, randomized trials that will tell whether this effect holds up when tested more rigorously and whether it lasts beyond the ten-month median observed here. If those trials confirm what CLARITY suggests, chlorophyllin could become standard care for a complication that has haunted cancer survivors for far too long.